ACADIA Pharmaceuticals Inc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | ACADIA Pharmaceuticals Inc |
Stock Symbol : | NASDAQ: ACAD |
Class Period Start: | 04/29/2016 |
Class Period End: | 07/09/2018 |
Lead Plaintiff motion: | 09/17/2018 |
Date Filed: | 07/19/2018 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Southern District of California |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the September 17, 2018 lead plaintiff deadline in a class action lawsuit filed against ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) (“ACADIA” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of California and investors, who purchased ACADIA Pharmaceuticals Inc securities between April 29, 2016 and July 9, 2018, have until September 17, 2018 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased ACADIA Pharmaceuticals Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that adverse events and safety concerns related to NUPLAZID threatened the drug’s initial and continuing FDA approval; that ACADIA engaged in business practices likely to attract regulatory scrutiny; and that, as a result of the foregoing, Defendants’ statements about ACADIA’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. On April 9, 2018, an article published by CNN questioned whether Acadia's Nuplazid treatment may have caused the deaths of sick and elderly patients. On this news, NASDAQ: ACAD dropped $5.03 per share or over 23% to close at $16.50 on April 9, 2018. On July 9, 2018, The Southern Investigative Reporting Foundation reported that that Acadia's "pursuit of regulatory approval is best described as 'loophole-centric.'" On this news, NASDAQ: ACAD dropped $1.21 per share or over 6.7% to close at $16.63 on July 9, 2018. If you were negatively impacted by your investment in ACADIA Pharmaceuticals Inc securities between April 29, 2016 and July 9, 2018 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |